Malignant peritoneal mesothelioma

Section editor
	Marjorie G. Zauderer, MD, MS, FACP Memorial Sloan Kettering Cancer Center New York, NY, USA

Last updated on 2024-07-23: 1 regimens on this page 1 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EURACAN/PSOGI

• 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up PubMed

NCCN

• NCCN Guidelines - Mesothelioma: Peritoneal
  • 2023: Ettinger et al. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. PubMed

Advanced or metastatic disease, subsequent lines of therapy

Atezolizumab & Bevacizumab

Regimen

Study	Dates of enrollment	Evidence
Raghav et al. 2021 (MDACC 2016-0861)	2017-2019	Phase 2

Immunotherapy

• Atezolizumab (Tecentriq) 1200 mg IV once on day 1

Targeted therapy

• Bevacizumab (Avastin) 15 mg/kg IV once on day 1

21-day cycles

References

1. MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT03074513